H.C. Wainwright Reiterates a Buy Rating on CytoDyn Inc (CYDY)

By Austin Angelo

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc (NYSEArca: CYDY) today and set a price target of $1.50. The company’s shares closed yesterday at $0.62.

Selvaraju observed:

“Our 12-month price target is derived from a market value of the firm at $470M, which includes a discounted cash flow-based asset value for PRO 140 in the HIV indication alone, with 15% discount rate, 2% terminal growth rate, and 80% probability of success. Risks include, but are not limited to: (1) failure of PRO 140 in clinical trials; (2) failure of PRO 140 to secure regulatory approval; (3) failure of PRO 140 to achieve commercial success due to market size, penetration rate, and/ or competition; and (4) dilution risk.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.3% and a 43.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.

CytoDyn Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.

See today’s analyst top recommended stocks >>

Based on CytoDyn Inc’s latest earnings release for the quarter ending May 31, the company reported a quarterly GAAP net loss of $9.62 million. In comparison, last year the company had a GAAP net loss of $11.63 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin.